Better Life Through Better Science
KaloBios is developing a proprietary portfolio of customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with cancer.
Recent Corporate Highlights
- Initiated Phase 2 expansion portion of clinical trial for KB004 in hematologic malignancies
- Announced preliminary Phase 1 results in advanced hematologic malignancies with KB004 at ASH Annual Meeting